ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: L05

Effect of Denosumab on Structure Modification in Erosive Hand Osteoarthritis: Results of a 48-Week, Monocentric, Randomized, Placebo-controlled, Double-blind Phase 2 Study and Open Label Extension Phase

Ruth Wittoek1, August Verbruggen2, Tine Vanhaverbeke2 and Dirk Elewaut3, 1Dept. of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Oost-Vlaanderen, Belgium, 2Ghent University Hospital, Ghent, Belgium, 3Ghent University and VIB Center for Inflammation Research, Ghent, Belgium

Meeting: ACR Convergence 2022

Date of first publication: October 18, 2022

Keywords: Late-Breaking 2022, Osteoarthritis, Randomized Trial, RANKL

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: Late-Breaking Abstracts (L01–L06)

Session Type: Late-Breaking Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: Erosive hand osteoarthritis (OA) is a disabling disease with limited therapeutic options. Denosumab, a Receptor Activator of Nuclear Factor kappa-b Ligand inhibitor, affects bone resorption and osteoclast activity. The purpose of this clinical trial was to study the structure modifying effect of denosumab in patients with erosive hand OA, and to explore the clinical benefits and safety of subcutaneous denosumab 60 mg every 3 months versus placebo.

Methods: One hundred patients with erosive hand OA were randomly allocated to placebo or denosumab in a monocentric clinical trial lasting 48 weeks, followed by an open-label extension phase through week 96. The primary radiographic endpoint was change in total Ghent University Scoring System (GUSS™) score at week 24. GUSS™ (0-300) is a semi-quantitative scoring system specifically developed to combine scoring of both aspects of radiographic changes in erosive hand OA, being erosive progression (decrease of score) and signs of repair (increase of score) (1) and able to detect changes on short term (2). The secondary endpoint was the percentage of new erosive joints at week 48. Exploratory imaging (ultrasound) and clinical outcomes (pain, tender joint count, swollen joint count, grip strength, the Australian-Canadian Hand Osteoarthritis Index and the Functional Index for Hand Osteoarthritis) were assessed. Radiographic and clinical changes after 96 weeks of treatments were measured. Safety outcomes including (serious) adverse events, laboratory changes and changes in bone mineral density by dual-energy X-ray absorptiometry were registered. Primary efficacy analyses were performed in an intention-to-treat approach. Changes in GUSS™ were analysed at joint level with generalized estimating equations, accounting for within-patient clustering. Robust standard errors were used and the working correlation structure specified exchangeable Trial registration number: EUDRACT CT 2015-003223-53.

Results: 51 and 49 patients received subcutaneous administration of denosumab and placebo respectively. Total change GUSS™ was found statistically higher in denosumab compared to placebo at week 24 (mean change GUSS™ = 8.9 (95% CI: 1.0 – 16.9; p = 0.024))(Figure 1). This difference further increased at week 48 (ΔGUSS™ = 14.3 (95% CI: 4.6 – 24.0; p = 0.003)). Development of new erosive joints was significantly lower in denosumab (1.8%) compared to placebo (7.0%) at week 48 (OR = 0.23 (95% CI: 0.10 to 0.50); p < 0.001) (Figure 2). After open-label treatment through week 96, both groups continued remodelling and both pain and function significantly improved compared to baseline. No difference in occurrence of adverse events were observed between both groups.

Conclusion: Denosumab has clear structure modifying effects in erosive hand OA compared to placebo: significantly less erosive progression occurs after 24 weeks treatment, and the treatment effect enhances after 48 weeks. Symptom improvement was observed after sustained treatment.

References:
1. Verbruggen G et al. Ann Rheum Dis. 2010 May;69(5):862-7
2. Verbruggen G et al. Ann Rheum Dis. 2012 Jun;71(6):891-8

Supporting image 1

Figure 1: Radiographic changes after 48-weeks placebo-controlled phase and extension phase through 96 weeks by the primary endpoint GUSS™

Supporting image 2

Figure 2: Radiographic changes after 48-weeks placebo-controlled phase and extension phase through 96 weeks by percentage of new erosive joints (secondary endpoint)


Disclosures: R. Wittoek, None; A. Verbruggen, None; T. Vanhaverbeke, None; D. Elewaut, Amgen.

To cite this abstract in AMA style:

Wittoek R, Verbruggen A, Vanhaverbeke T, Elewaut D. Effect of Denosumab on Structure Modification in Erosive Hand Osteoarthritis: Results of a 48-Week, Monocentric, Randomized, Placebo-controlled, Double-blind Phase 2 Study and Open Label Extension Phase [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/effect-of-denosumab-on-structure-modification-in-erosive-hand-osteoarthritis-results-of-a-48-week-monocentric-randomized-placebo-controlled-double-blind-phase-2-study-and-open-label-extension-pha/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-denosumab-on-structure-modification-in-erosive-hand-osteoarthritis-results-of-a-48-week-monocentric-randomized-placebo-controlled-double-blind-phase-2-study-and-open-label-extension-pha/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology